3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Cisplatin
47
Radiotherapy
37
Fluorouracil
23
Cetuximab
17
pembrolizumab
11
Carboplatin
11
Paclitaxel
8
Docetaxel
8
Radiotherapy, Intensity-Modulated
6
Chemotherapy, Adjuvant
6
Surgical Procedures, Operative
5
Standard of Care
5
nimotuzumab
4
Methotrexate
4
Gabapentin
4
Drug Therapy
4
Afatinib
4
Radiotherapy, Conformal
3
Radiation
3
Porfiromycin
3
Nivolumab
3
Neoadjuvant Therapy
3
Fibroblast Growth Factor 7
3
Bleomycin
3
zalutumumab
2
sargramostim
2
epacadostat
2
Tranexamic Acid
2
Tirapazamine
2
Pilocarpine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Head and Neck Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled